4-Neopentyl-phenylessigsaeure | 42288-64-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Neopentyl-phenylessigsaeure
• 英文别名: 2-[4-(2,2-Dimethylpropyl)phenyl]acetic acid
• CAS: 42288-64-2
• 化学式: C₁₃H₁₈O₂
• 分子量: 206.285
• InChiKey: ALDFGGOEJPJWRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Heterocyclic Substituted Pyrimidine Compound
  申请人：Wu Yongqian

  公开号：US20140288063A1

  公开（公告）日：2014-09-25

  The present invention pertains to the field of medical technology, and particularly relates to a heterocyclic substituted pyrimidine compound represented by General Formula (I) and its pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description, the present invention also relates to a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition in preparation of a medicine for enhancing a cGMP signal transduction function or a medicine for treating or preventing sexual dysfunction and diseases with lower urinary tract symptoms.

  本发明涉及医学技术领域，特别涉及一种由通用公式（I）表示的杂环取代嘧啶化合物及其在药学上接受的盐，其中R1、R2、R3、R4和R5如描述中所定义，本发明还涉及该化合物的制备方法、含有该化合物的药物组合物，以及该化合物和药物组合物在制备增强cGMP信号转导功能的药物或治疗或预防性功能障碍和下尿路症状疾病的药物中的用途。
• ORGANIC COMPOUNDS AND THEIR USES
  申请人：Brandl Trixl

  公开号：US20100204159A1

  公开（公告）日：2010-08-12

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

  本申请描述了对人类疾病的治疗、预防和/或改善有用的有机化合物。
• Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators
  申请人：Edmondson Scott

  公开号：US20100113492A1

  公开（公告）日：2010-05-06

  Certain novel substituted aminopyrimidines are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

  某些新型取代氨基嘧啶是人体胆囊收缩素受体的配体，特别是人体胆囊收缩素-1受体（CCK-1R）的选择性配体。因此，它们对于治疗、控制或预防对CCK-1R调节敏感的疾病和疾病是有用的，例如肥胖症和糖尿病。
• Bicyclic Substituted Pyrimidine Compounds
  申请人：Xuanzhu Pharma Co., Ltd.

  公开号：US20150232474A1

  公开（公告）日：2015-08-20

  Disclosed are bicyclic group substituted pyrimidine compounds, pharmaceutical acceptable salts thereof or stereoisomers thereof. Also disclosed are preparation methods, pharmaceutical formulations, and pharmaceutical compositions of the compounds, and use of the compounds, pharmaceutical formulations, and pharmaceutical compositions for preparing a medicament for treating and/or preventing sexual dysfunction diseases and diseases with lower urinary tract symptoms.

  本发明涉及含有双环基团取代的嘧啶化合物，其药用可接受的盐或立体异构体。本发明还涉及该化合物的制备方法、制药配方和制药组合物，以及使用该化合物、制药配方和制药组合物制备用于治疗和/或预防性功能障碍疾病和下尿路症状的药物。
• JPH07304688A
  申请人：——

  公开号：JPH07304688A

  公开（公告）日：1995-11-21